Literature DB >> 31240570

Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects.

Nuggehally R Srinivas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31240570     DOI： 10.1007/s13318-019-00566-8

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN： 0378-7966            Impact factor:   2.441


× No keyword cloud information.
  11 in total

1.  IL-1Ra selectively protects intestinal crypt epithelial cells, but not tumor cells, from chemotoxicity via p53-mediated upregulation of p21(WAF1) and p27(KIP1.).

Authors:  Xia Wang; Shunying Zhu; Lan Qian; Jing Gao; Mingyuan Wu; Jin Gao; Yang Zhang; Gerald L Chan; Yan Yu; Wei Han
Journal:  Pharmacol Res       Date:  2014-03-28       Impact factor: 7.658

2.  Recombinant human interleukin-1 receptor antagonist reduces acute lethal toxicity and protects hematopoiesis from chemotoxicity in vivo.

Authors:  Lan Qian; Di Xiang; Jing Zhang; Shunying Zhu; Jin Gao; Xia Wang; Jing Gao; Yang Zhang; Jiaqing Shen; Yan Yu; Wei Han; Mingyuan Wu
Journal:  Biomed Pharmacother       Date:  2012-11-23       Impact factor: 6.529

3.  Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.

Authors:  Roy M Fleischmann; Joy Schechtman; Ralph Bennett; Malcolm L Handel; Gerd-Rudiger Burmester; John Tesser; Dennis Modafferi; Jennifer Poulakos; Gordon Sun
Journal:  Arthritis Rheum       Date:  2003-04

4.  Interleukin-1 receptor antagonist attenuates cyclophosphamide-induced mucositis in a murine model.

Authors:  Di Xiang; Yiping Guo; Jing Zhang; Jin Gao; Huili Lu; Shunying Zhu; Mingyuan Wu; Yan Yu; Wei Han
Journal:  Cancer Chemother Pharmacol       Date:  2010-09-03       Impact factor: 3.333

5.  Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects.

Authors:  R H Barbhaiya; C A Knupp; J Tenney; R R Martin; D J Weidler; K A Pittman
Journal:  J Clin Pharmacol       Date:  1990-10       Impact factor: 3.126

6.  Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.

Authors:  Stanley Cohen; Eric Hurd; John Cush; Michael Schiff; Michael E Weinblatt; Larry W Moreland; Joel Kremer; Moraye B Bear; William J Rich; Dorothy McCabe
Journal:  Arthritis Rheum       Date:  2002-03

7.  Exogenous IL-1Ra attenuates intestinal mucositis induced by oxaliplatin and 5-fluorouracil through suppression of p53-dependent apoptosis.

Authors:  Xia Wang; Jin Gao; Lan Qian; Jing Gao; Shunying Zhu; Mingyuan Wu; Yang Zhang; Wen Guan; Hao Ye; Yan Yu; Wei Han
Journal:  Anticancer Drugs       Date:  2015-01       Impact factor: 2.248

8.  Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis.

Authors:  B W Deleuran; C Q Chu; M Field; F M Brennan; P Katsikis; M Feldmann; R N Maini
Journal:  Br J Rheumatol       Date:  1992-12

9.  Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.

Authors:  Bénédicte Neven; Isabelle Marvillet; Celine Terrada; Alice Ferster; Nathalie Boddaert; Vincent Couloignier; Graziella Pinto; Anne Pagnier; Christine Bodemer; Bahram Bodaghi; Marc Tardieu; Anne Marie Prieur; Pierre Quartier
Journal:  Arthritis Rheum       Date:  2010-01

10.  Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects.

Authors:  Ran Xie; Yang Zhang; Nan Zhao; Shuang Zhou; Xin Wang; Wei Han; Yan Yu; Xia Zhao; Yimin Cui
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-06       Impact factor: 2.441
View more
  1 in total

1.  Author's Reply to: "Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Chinese Healthy Subjects".

Authors:  Ran Xie; Yang Zhang; Nan Zhao; Shuang Zhou; Xin Wang; Wei Han; Yan Yu; Xia Zhao; Yimin Cui
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-10       Impact factor: 2.441
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.